Australia's most trusted
source of pharma news
Tuesday, 2 June 2026
Tuesday, 2 June 2026
Subscribe
Login
Price cuts hit $168M in PBS brands
Three PBS listed drugs which earned around $168 million combined in 2025 face generic competition for the first time from June meaning a 25 per cent statutory reduction in price.
GSK shuffles Govt Affairs team
Leader promoted into an international position - see which colleague has stepped into the Australian Govt Affairs & Policy role
TODAY
Pfizer rolls dice on 12 cancer drugs
Doubling down in oncology with a deal worth up to US$10.5 billion with a Chinese biotech to develop a dozen new cancer therapies
TODAY
More Aussie pharma jobs go
This Big Pharma says its future depends on becoming even more resilient and agile in the face of mounting industry pressures
1 June
June PBS listings unpacked
Changes to the PBS listings of a BTK and a bispecific T-cell engagers has been made alongside the introduction of an additional adrenaline autoinjector
1 June New to the PBS
Serious adverse event warning
After errors by doctors overseas, the TGA has issued a warning about the risks of incorrect administration of this drug
29 May
Industry pay stalls, feet get itchy
Average pay across Aussie pharma and life sciences stalls but that's not the only reason employees are eyeing other opportunities
29 May
Latest Jobs
Equipment Sales Specialist - DentalTerritory ManagerMarketing Manager ANZKey Account ManagerClinical Trial InvestigatorSenior Group Financial AccountantTalent Acquisition CoordinatorSenior Medical Manager24 more...
Pharma in Focus Jobs
Marketing & Communications (1)
Sales & Customer Relations (18)
- Equipment Sales Specialist - Dental - Sydney
- Territory Manager - Melbourne
- Key Account Manager - Melbourne
- Senior Group Financial Accountant - Victoria
- Strategic Sales Director ANZ, Digital Health - Melbourne
- Strategic Sales Director ANZ, Digital Health - Sydney
- Sales Manager / Territory Manager - Christchurch
- Business Development Manager – Health Tech - Melbourne
- GP Representative - Geelong
- Business Development Manager – Health Tech - Brisbane
- Business Development Manager, Health Tech - Sydney
- Territory Manager - Gold Coast
- Sales Director - Sydney
- Medical Sales Representative - Sydney
- Business Development Manager - Sydney
- Specialty Pharmaceutical Sales Representative - Queensland
- Surgical Sales Specialist - Auckland
- Surgical Sales Specialist - Auckland
Clinical & Medical, R&D (5)
- Clinical Trial Investigator - Melbourne
- Senior Medical Manager - Melbourne
- Clinical Trial Start Up Specialist - Melbourne
- Medical Sales Representative - Sydney
- Clinical Trial Nurse Unit Manager - Melbourne
Regulatory, Pharmacovigilance & QA (2)
Executive Roles (4)
- Strategic Sales Director ANZ, Digital Health - Melbourne
- Strategic Sales Director ANZ, Digital Health - Sydney
- Director of Operations, HealthTech - Melbourne
- Sales Director - Sydney
Other (7)
TGA tick highlights genetic testing
Approval for a targeted drug shines a light on the need to increase community awareness of genetic testing
1 June
New Parkinson's drug approved
Tick for a systemic transdermal treatment patch containing an active sponsored by another company for a different indication
1 June Approvals Action
Who's won a June PBS listing?
Partnership unveiled to support the introduction, distribution, and education of the now subsidised medicine across Australia
1 June
Market leader falls for first time
ICYMI: There's been a major shift in industry's therapeutic focus with oncology toppled plus the other most popular stories this week
29 May Your Week in 5 minutes
Backlash over Govt ad campaign
High-profile women's health campaign triggers anger from patients over two important drugs that are out of reach
29 May
Investor targets 'untapped market'
Sydney-based private investment firm is spearheading a push to build business around women's health, committing $25M-plus
29 May
Senior exec leaves pharma
New job, new industry plus the other employment moves across industry, including a farewell after 26 years
28 May
Why Drs are losing trust in pharma
Uncoordinated messaging can leave HCPs with a low opinion of pharmas even when individual teams are successful
28 May
Drug class doubles in one month
A third new approval has seen this drug class double in size in just one month, and marks the first-ever Australian product approval for the pharma
28 May
$17.7B bid to take pharma private
A private equity firm and Belgian investment group have launched a $17.7 billion bid to take this pharmaceutical company private
28 May
Lilly muscles into vaccine market
Obesity giant puts $5 billion-plud on the table for next-gen technologies that target diseases with no approved rivals
28 May
TGA teases four drug approvals
Four companies could be on the cusp of having their drugs approved by the TGA and at least one is a potential blockbuster
27 May
Drug pulled after viability review
Pharma to discontinue supply after assessing the commercial viability of its products and a review of future market demand and product volumes
27 May
Exec exits with pointed sign-off
After 19 years with the same company this Sydney-based leader has left his role with the final word about 'organisational decisions'
27 May